Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines

Oncology Letters

Volumn 5, Issue 6, 2013, Pages 1765-1770

  Fujisue, Yutaka ^a   Nakagawa, Takatoshi ^a   Takahara, Kiyoshi ^a   Inamoto, Teruo ^a   Kiyama, Satoshi ^a   Azuma, Haruhto ^a   Asahi, Michio ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Erythropoietin; Hypoxia inducible factor 1; Renal cell carcinoma

Indexed keywords

COBALT CHLORIDE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; SMALL INTERFERING RNA;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84876462078     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1283     Document Type: Article

References (41)

1. Koury ST, Bondurant MC, Koury MJ and Semenza GL: Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77: 2497-2503, 1991.
2. Krantz SB: Erythropoietin. Blood 77: 419-434, 1991.
3. Youssoufian H, Longmore G, Neumann D, et al: Structure, function, and activation of the erythropoietin receptor. Blood 81: 2223-2236, 1993.
4. Sasaki R, Masuda S and Nagao M: Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem 64: 1775-1793, 2000.
5. Winkelmann JC: The human erythropoietin receptor. Int J Cell Cloning 10: 254-261, 1992.
6. Vogt C, Pentz S and Rich IN: A role for the macrophage in normal hemopoiesis: III. In vitro and in vivo erythropoietin gene expression in macrophages detected by in situ hybridization. Exp Hematol 17: 391-397, 1989.
7. Anagnostou A, Liu Z, Steiner M, et al: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91: 3974-3978, 1994.
8. Masuda S, Nagao M, Takahata K, et al: Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268: 11208-11216, 1993.
9. Ogilvie M, Yu X, Nicolas-Metral V, et al: Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 275: 39754-39761, 2000.
10. Yasuda Y, Masuda S, Chikuma M, et al: Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 273: 25381-25387, 1998.
11. Juul SE, Zhao Y, Dame JB, et al: Origin and fate of erythro-poietin in human milk. Pediatr Res 48: 660-667, 2000.
12. Trimble M, Caro J, Talalla A and Brain M: Secondary eryth-rocytosis due to a cerebellar hemangioblastoma: demonstration of erythropoietin mRNA in the tumor. Blood 78: 599-601, 1991.
13. Bruneval P, Sassy C, Mayeux P, et al: Erythropoietin synthesis by tumor cells in a case of meningioma associated with erythro-cytosis. Blood 81: 1593-1597, 1993.
14. Yasuda Y, Musha T, Tanaka H, et al: Inhibition of erythropoietin signaling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84: 836-843, 2001.
15. Acs G, Zhang PJ, Rebbeck TR, et al: Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95: 969-981, 2002.
16. Semenza GL: Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med 131: 207-214, 1998.
17. Semenza GL: Hypoxia and cancer. Cancer Metastasis Rev 26: 223-224, 2007
18. Du R, Lu KV, Petritsch C, et al: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13: 206-220, 2008.
19. Powis G and Kirkpatrick L: Hypoxia inducible factor. alpha as a cancer drug target. Mol Cancer Ther 3: 647-654, 2004
20. Ihle JN, Witthuhn BA, Quelle FW, et al: Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 19: 222-227, 1994
21. Mulcahy L: The erythropoietin receptor. Semin Oncol 28 (2 Suppl 8): 19-23, 2001.
22. Leyland-Jones B: Trastuzumab: hopes and realities. Lancet Oncol 3: 137-144, 2002.
23. Westenfelder C and Baranowski RL: Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647-657, 2000.
24. Ito K, Yoshii H, Asano T, et al: Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma. Exp Ther Med 3: 937-944, 2012.
25. Laugsch M, Metzen E, Svensson T, et al: Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 122: 1005-1011, 2008.
26. Lee YS, Vortmeyer AO, Lubensky IA, et al: Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 11: 1059-1064, 2005
27. Maxwell PH and Ratcliffe PJ: Oxygen sensors and angiogenesis. Semin Cell Dev Biol 13: 29-37, 2002.
28. Kaelin WG Jr: Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2: 673-682, 2002.
29. Lee R, Kertesz N, Joseph SB, et al: Erythropoietin (Epo) and EpoR expression and 2 waves of erythropoiesis. Blood 98: 1408-1415, 2001.
30. Mitjavila MT, Le Couedic JP, Casadevall N, et al: Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro. J Clin Invest 88: 789-797, 1991.
31. Wang GL and Semenza GL: General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90: 4304-4308, 1993.
32. Acs G, Chen M, Xu X, et al: Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 214: 243-251, 2004
33. Wincewicz A, Koda M, Sulkowska M, et al: STAT3 and hypoxia induced proteins - HIF-1alpha, EPO and EPOR in relation with Bax and Bcl-xL in nodal metastases of ductal breast cancers. Folia Histochem Cytobiol 47: 425-430, 2009
34. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
35. Semenza GL: Defning the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634, 2010.
36. McCarty MF, Barroso-Aranda J, and Contreras F Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy. Med Hypotheses 74: 789-797, 2010.
37. Turner KJ, Moore JW, Jones A, et al: Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62: 2957-2961, 2002.
38. Ohh M, Park CW, Ivan M, et al: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427, 2000.
39. Gong K, Zhang N, Zhang K and Na Y: The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma. Int J Mol Med 26: 907-912, 2010.
40. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
41. Miyazaki M, Yasuda M, Fujita M, et al: Therapeutic strategy targeting the mTOR-HIF-1α-VEGF pathway in ovarian clear cell adenocarcinoma. Path Int 59: 19-27, 2009